Bicycle Therapeutics

Bicycle Therapeutics is a biotechnology company based in Cambridge, UK, with operations in Cambridge, MA. The company specializes in developing precision-guided therapeutics aimed at treating solid tumors and other diseases. Bicycle Therapeutics is focused on creating innovative treatments that effectively penetrate tissues to target challenging cancers. The company's core technology involves fully synthetic short peptides that are constrained with small molecule scaffolds, allowing for high affinity and selectivity in target binding. Bicycle's proprietary Bicycle® molecules are designed to address difficult therapeutic targets. The company is currently evaluating several therapeutic candidates in clinical development, including BT5528, BT8009, BT7480, and BT1718, all of which are in various Phase I/II trials. Bicycle Therapeutics primarily focuses on oncology but is also exploring applications in other therapeutic areas through collaborations with pharmaceutical partners and academic institutions. These areas include anti-infective, cardiovascular, ophthalmology, dementia, central nervous system, neuromuscular, and respiratory diseases.